Chronic tinnitus, noise or ringing in the ears, is a symptom associated with many forms of hearing loss or other health problems. There are no effective treatments for this condition, which can become so severe that it may be difficult to hear, work, or even sleep.
Researchers at the University of Pennsylvania are now testing a non-invasive treatment – transcranial magnetic stimulation (TMS) – to target overactive areas in the brain responsible for tinnitus. TMS was recently approved by the United States Food and Drug Administration (FDA) for treatment of depression and has been extensively tested in Europe for tinnitus.
Michael Ruckenstein, MD, Professor of Otorhinolaryngology: Head and Neck Surgery at the Perelman School of Medicine, will lead the study, in conjunction with John O’Reardon, Associate Professor of Psychiatry and Director of Penn’s Transcranial Magnetic Stimulation Program. Study participants will undergo 4 weeks (20 sessions) of TMS sessions to see if the treatment improves tinnitus. For those who respond, there will be a 3 month extension phase (8 sessions – 4 in month 1, 2 each in months 2 and 3).
Adults may be eligible for the trial if they have had chronic tinnitus for more than 6 months and do not have any neurological or psychiatric conditions. For more information on this study, please contact 215-614-0036.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.